

REMARKS

Claims 69-96 are pending in the subject application. Claims 1-68 have been canceled. Claims 69, 81, 91, 93, 94 and 96 have been amended to clarify the claimed subject matter.

Claim 69 has been amended to recite as an independent claim.

Claims 81, 91, 93 and 94 have been amended to depend from claim 69.

Claim 91 has also been amended on page 45, line 32 to delete the number "1" after the term "hydrate."

Claim 96 has been amended on page 46, line 22 to add a semicolon after the phrase "wherein each R⁵ and R⁶ is independently selected from H or C₁-C₆ alkyl," and to replace the term "substituitents" on page 46, line 20 with the term "substituents."

Support for the amendments to claims 69, 81, 91, 93, 94, and 96 can be found, for example, in original claims 69, 81, 91, 93, 94 and 96, respectively.


No new matter has been added. Entry of this Amendment is respectfully requested.

CONCLUSION

Applicants respectfully request prompt consideration of the pending claims and early allowance of the application. No additional fee is believed due. However, if any fee is due, the Examiner is authorized to charge the fee to Applicants' Deposit Account No. 16-1445.

If the Examiner wishes to comment or discuss any aspect of this application or response, applicants' undersigned agent invites the Examiner to call him at the telephone number provided below.

Respectfully submitted,



David L. Kershner
Agent for Applicants
Reg. No. 53,112

Date: September 29, 2005

Pfizer Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-0538